Visiting Professors: Lung Cancer Edition — Part 2: Our
discussion with Drs Horn and Ma highlights the following topics as
well as cases from Dr Ma’s practice:
Case: A woman in her mid-70s with Stage IV
lung adenocarcinoma and a PD-L1 TPS of 70% experiences a pathologic
fracture of the right femur while receiving first-line
pembrolizumab
(00:00)
Pembrolizumab monotherapy versus
carboplatin/pemetrexed/pembrolizumab as first-line therapy for
patients with metastatic NSCLC and a high TPS (02:30)
Radiation necrosis as a potential cause of pathologic fractures
(05:18)
Thyroid dysfunction and pancreatitis associated with
pembrolizumab (08:12)
Case: A man in his early 50s with metastatic
lung cancer of ambiguous histology experiences a dramatic response
to first-line nab paclitaxel/carboplatin
(11:11)
Utility of liquid biopsies in therapeutic decision-making for
patients with metastatic lung cancer (13:03)
Therapy for patients with metastatic lung cancer and CNS
metastases (15:11)
Therapeutic approach for patients with metastatic lung cancer
of undetermined histology (20:30)
Second-line therapy for patients with metastatic lung cancer
(22:41)
Case: A woman in her mid-80s with metastatic
lung adenocarcinoma and a PD-L1 TPS of 30% receives
pemetrexed/pembrolizumab and experiences dyspnea
(28:14)
Perspective on the approach to metastatic lung adenocarcinoma
in elderly patients (30:52)
Efficacy of ramucirumab as second-line therapy for patients
with metastatic NSCLC (36:24)
REVEL: Results of a Phase III trial evaluating the addition of
ramucirumab to docetaxel after disease progression on
platinum-based therapy for patients with Stage IV NSCLC
(37:44)
Comparison of the activity and tolerability of ramucirumab to
that of bevacizumab in patients with metastatic squamous cell
carcinoma of the lung (40:11)
Ongoing clinical investigation of novel combination approaches
with immune checkpoint inhibitors and anti-angiogenic agents
(41:49)
Case: A man in his mid-70s, a former smoker,
with Stage III NSCLC initially treated with adjuvant chemoradiation
therapy develops metastatic disease and is found to have a RET
tumor mutation
(43:40)
Effects of tumor mutation burden and PD-L1 expression on
response to immune checkpoint inhibitors (47:32)
Perspective on the use of targeted therapy as first-line
treatment for patients with metastatic NSCLC (49:32)
Sequencing targeted therapy and immune checkpoint inhibitors
for patients with metastatic NSCLC and actionable tumor mutations
(51:08)
Case: A woman in her early 60s with lung
adenocarcinoma and oligometastatic disease in the brain receives
first-line chemoradiation therapy
(56:39)
Cardiomyopathy associated with checkpoint inhibitor therapy
(1:00:08)
Prolonged responses to anti-PD-1/PD-L1 antibodies after
cessation of therapy (1:03:27)
PD-L1 expression as a predictor of response to immune
checkpoint inhibitors (1:07:40)
Case: A man in his early 70s with metastatic
NSCLC develops a severe carboplatin-related allergy during
treatment with carboplatin/nab paclitaxel/pembrolizumab
(1:09:41)
Benefits of early palliative care in the management of
metastatic NSCLC (1:15:22)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.